Voya Financial Advisors Inc. Purchases 5,321 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Voya Financial Advisors Inc. increased its stake in IQVIA Holdings Inc. by 41.4% in Q2, owning a total of 18,177 shares valued at approximately $2.86 million after acquiring an additional 5,321 shares.
• Institutional investors currently hold 89.62% of IQVIA's shares, indicating strong interest among large financial entities.
• IQVIA reported earnings of $2.81 per share for the last quarter, surpassing analysts' expectations of $2.77 and reflecting a year-over-year revenue growth of 5.3%.

Voya Financial Advisors Inc. raised its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 41.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,177 shares of the medical research company's stock after purchasing an additional 5,321 shares during the quarter. Voya Financial Advisors Inc.'s holdings in IQVIA were worth $2,862,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Artisan Partners Limited Partnership bought a new position in shares of IQVIA during the second quarter worth about $515,772,000. Norges Bank bought a new position in shares of IQVIA during the second quarter worth about $270,160,000. AQR Capital Management LLC raised its position in shares of IQVIA by 130.2% during the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company's stock worth $245,099,000 after acquiring an additional 879,701 shares during the last quarter. Pacer Advisors Inc. raised its position in shares of IQVIA by 5,036.1% during the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company's stock worth $153,681,000 after acquiring an additional 854,732 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of IQVIA by 45.7% during the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock worth $448,686,000 after acquiring an additional 798,534 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of analyst reports. Cowen restated a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. William Blair restated an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Redburn Partners set a $214.00 price objective on IQVIA in a research report on Wednesday, September 3rd. Robert W. Baird raised their price objective on IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Finally, Jefferies Financial Group upgraded IQVIA from a "hold" rating to a "buy" rating and lifted their target price for the stock from $195.00 to $225.00 in a report on Tuesday, September 9th. Eighteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $229.64.

IQVIA Trading Up 1.6%

Shares of IQV stock opened at $179.51 on Friday. The company has a market cap of $30.52 billion, a P/E ratio of 25.98, a PEG ratio of 1.94 and a beta of 1.32. The stock has a 50 day simple moving average of $187.01 and a two-hundred day simple moving average of $167.28. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $237.34.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same period in the previous year, the company posted $2.64 earnings per share. The firm's revenue for the quarter was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Buying and Selling

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares of the company's stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.